We are live on ! Find out more
CNTA

Centessa Pharmaceuticals
CNTA

Delisted

CNTA was delisted on the 23rd of June, 2026.

Back to rankings

69 hedge funds and large institutions have $841M invested in Centessa Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 27 increasing their positions, 7 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

286% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 7

181% more call options, than puts

Call options by funds: $216K | Put options by funds: $77K

157% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 7

150% more funds holding in top 10

Funds holding in top 10: 2 → 5 (+3)

46% more capital invested

Capital invested by funds: $577M → $841M (+$264M)

19% more funds holding

Funds holding: 58 → 69 (+11)

1.95% more ownership

Funds ownership: 74.25% → 76.2% (+1.9%)

Holders
69
Holders Change
+11
Holders Change %
+18.97%
% of All Funds
0.99%
Holding in Top 10
5
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+150%
% of All Funds
0.07%
New
18
Increased
27
Reduced
7
Closed
7
Calls
$216K
Puts
$77K
Net Calls
+$139K
Net Calls Change
+$2K

Top Buyers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
+$29.2M
2
FLAM
First Light Asset Management
Minnesota
+$28.4M
3
5VM
5AM Venture Management
California
+$11.8M
4
DCM
Driehaus Capital Management
Illinois
+$7.71M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$3.96M

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$69.8M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$6.12M
3
KCM
Kynam Capital Management
New Jersey
-$3.52M
4
Morgan Stanley
Morgan Stanley
New York
-$2.75M
5
WP
Woodline Partners
California
-$1.12M
Name Holding Trade Value Shares
Change 		Change in
Stake
PHS
26
PFM Health Sciences
California
$3.56M +$2.98M +314,674 New
Millennium Management
27
Millennium Management
New York
$3.25M +$2.32M +244,906 +576%
EAM
28
Exome Asset Management
New York
$3.11M +$2.6M +274,900 New
Balyasny Asset Management
29
Balyasny Asset Management
Illinois
$2.88M +$2.41M +254,446 New
Marshall Wace
30
Marshall Wace
United Kingdom
$2.62M +$2.19M +231,565 New
TD Asset Management
31
TD Asset Management
Ontario, Canada
$2.58M +$401K +42,334 +23%
Renaissance Technologies
32
Renaissance Technologies
New York
$2.47M +$314K +33,200 +18%
ACM
33
ADAR1 Capital Management
Texas
$2.34M +$1.96M +206,856 New
Ensign Peak Advisors
34
Ensign Peak Advisors
Utah
$1.41M – – –
Manulife (Manufacturers Life Insurance)
35
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.22M +$426K +45,027 +71%
TI
36
Trexquant Investment
Connecticut
$1.09M +$778K +82,177 +573%
LCM
37
Landscape Capital Management
New Jersey
$1.02M +$855K +90,240 New
Two Sigma Investments
38
Two Sigma Investments
New York
$890K +$590K +62,281 +377%
Bank of America
39
Bank of America
North Carolina
$870K +$378K +39,954 +108%
CSS
40
Cubist Systematic Strategies
Connecticut
$820K +$642K +67,785 +1,405%
PCM
41
Prelude Capital Management
New York
$781K +$654K +69,109 New
Goldman Sachs
42
Goldman Sachs
New York
$622K +$287K +30,296 +123%
Citadel Advisors
43
Citadel Advisors
Florida
$531K -$510K -53,836 -53%
Geode Capital Management
44
Geode Capital Management
Massachusetts
$379K – – –
JF
45
Jump Financial
Illinois
$371K +$176K +18,573 +130%
RG
46
Rathbones Group
United Kingdom
$354K – – –
Acadian Asset Management
47
Acadian Asset Management
Massachusetts
$330K +$278K +29,409 New
JP Morgan Chase
48
JP Morgan Chase
New York
$308K +$158K +16,635 +156%
LCM
49
Lynx1 Capital Management
Puerto Rico
$197K +$165K +17,400 New
GCP
50
GSA Capital Partners
United Kingdom
$154K +$129K +13,587 New
1
2
3 4

CNTA Hedge Fund Activity: Q1 2024 in Review

69 of the 6,946 institutional investors tracked by Wall St. Rank reported a position in Centessa Pharmaceuticals (CNTA) for Q1 2024, worth a combined $841M — up 46% from $577M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new CNTA positions and 7 closed out — a net gain of 11 holders — while 27 added to existing stakes and 7 trimmed.

The largest buyer was Perceptive Advisors, opening a new position worth an estimated $29.2M. The largest seller was BVF Inc, exiting entirely with an estimated $69.8M sold.

  • 69 institutional investors held Centessa Pharmaceuticals (CNTA) as of Q1 2024, up from 58 in Q4 2023.
  • Funds reported $841M of Centessa Pharmaceuticals stock for Q1 2024, up 46% quarter-over-quarter.
  • 18 funds opened new Centessa Pharmaceuticals positions in Q1 2024 and 7 closed out, a net change of +11 holders.
  • The largest Centessa Pharmaceuticals buyer in Q1 2024 was Perceptive Advisors, an estimated $29.2M added.
  • The largest Centessa Pharmaceuticals seller in Q1 2024 was BVF Inc, an estimated $69.8M sold.

Based on aggregated 13F filings for Q1 2024.